Answers are grounded in this paper and cite their sources.
Objective Endometriosis may cause persistent pelvic pain, pelvic-floor dysfunction, urinary sequelae, and restrictions in daily life. Electrical neuromodulation has been applied at peripheral, pelvic, sacral, spinal, and cortical targets, but its clinical uses remain dispersed. This review mapped the modalities, treatment parameters, outcomes, and delivery characteristics of electrical neuromodulation in endometriosis. Methods Following Joanna Briggs Institute methodology and Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews reporting, six databases (PubMed, Embase, CINAHL Complete, Scopus, Web of Science Core Collection, and Cochrane CENTRAL) were searched from inception through July 31, 2026. Primary clinical studies of electrical neuromodulation in endometriosis were eligible. Findings were descriptively mapped by modality, stimulation dose, anatomical target, outcome, safety, and durability. Results Seventeen reports from eight countries mapped six modality groups to distinct clinical purposes, spanning adjunctive pain management, central pain modulation, pelvic-floor activity, postoperative voiding dysfunction, and refractory pain. Controlled evaluations reported pain improvement, whereas pelvic-floor and urinary findings were drawn largely from exploratory or observational studies. Treatment targets and clinical populations differed, ranging from noninvasive adjuncts to implanted systems in selected patients with persistent symptoms. Functional outcomes, quality of life, analgesic use, catheter dependence, and device-related burden broadened the assessment beyond analgesia. Delivery demands and follow-up varied across these applications, limiting direct comparisons and underscoring the need to distinguish symptom relief from physiological change and functional recovery. Conclusions Electrical neuromodulation has been investigated for distinct symptoms and functional problems in endometriosis. Modality-specific trials should use reproducible protocols, functional outcomes, explicit safety and treatment-burden reporting, and appropriate follow-up.
No takes yet. Share an insight, caveat, or question.
Narvaez et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: